anti rabies medicine use in preventing rabies after animal bite
Phase 3
- Conditions
- Health Condition 1: Z203- Contact with and (suspected) exposure to rabies
- Registration Number
- CTRI/2020/02/023126
- Lead Sponsor
- Bharat serums and Vaccines ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with Category III exposure to Rabies
Exclusion Criteria
History of rabies vaccination
Known allergy to immunoglobulins
Suffering from a bleeding disorder
Receiving treatment with immunosuppressive agents
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of subjects achieving serum rabies virus neutralizing antibodies (RVNA) titre â?¥ 0.5 IU/mLTimepoint: On Day 14 post administration of IP
- Secondary Outcome Measures
Name Time Method umber of subjects with mortality due to post-exposure prophylaxis failureTimepoint: End of study